Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Hollings Mulling Salary Suspension For FTC Chairman, Commissioners

This article was originally published in The Tan Sheet

Executive Summary

A potential salary suspension for the Federal Trade Commission's five commissioners and senior staff, if enacted, would slow down the majority of FTC's operations indefinitely, according to the agency

You may also be interested in...



FTC/DoJ clearance procedures

Any future agreement on merger clearance procedures would have to satisfy Senate Commerce Committee Chairman Fritz Hollings' (D-S.C.) concerns about concurrent jurisdiction, particularly for media mergers. FTC, DoJ notified Hollings, who also chairs Senate Appropriations/Commerce Subcommittee, May 20 that they would not adhere to March 5 agreement that divvied up jurisdiction by industry (1"The Tan Sheet" April 22, 2002, p. 15). DoJ cited "prospect of budgetary consequences" if it stood by original agreement; supplemental appropriations bill, marked up in Senate May 22, was potential vehicle for budget and salary cuts for both agencies...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel